Work

P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC

Year: 2017

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2016.11.1668

Authors: Hatim Husain, Renato Martins, Sarah Goldberg, Peggy Senico, Wendy Ma, Joanna Masters, Nuzhat Pathan, Dong-Wan Kim, Mark Socinski, Zelanna Goldberg, Byoung Chul Cho

Institutions: Moores Cancer Center, Seattle Cancer Care Alliance, Yale Cancer Center, Yale University, Pfizer (United States), Seoul National University, Seoul National University Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2568710896

FWCI: 2.033

Cites:

Cited by: 15

Related to: 10